摘要：Analysis of 170 leading and emerging therapeutic antibodies (Ab) and vaccine companies unveils two different business growth trends. The therapeutic antibodies sector will see strong revenue growth with 15 new fully human and humanised product launches and its sales growing from US$5bn in 2002 to more than US$16bn in 2008. However, the therapeutic vaccines sector, despite its highly innovative nature and newly developed personalised approach, is unlikely to be able to achieve high market penetration with 2008 sales forecast less than US$0.5bn.
